ORAL VINORELBINE PLUS CISPLATIN VERSUS PEMETREXED PLUS CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A COST MINIMIZATION ANALYSIS IN TWELVE EUROPEAN COUNTRIES

被引：0
|
作者：
Bucher, D. [1 ]
Grossi, F. [2 ]
机构：
[1] Pierre Fabre, Boulogne Billancourt, France
[2] Natl Inst Canc Res, Genoa, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1112
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN96
引用
收藏
页码：A446 / A446
页数：1
相关论文
共 50 条
  • [21] The cost-effectiveness of bevacizumab plus cisplatin and gemcitabine (BCG) compared with pemetrexed plus cisplatin (PC) induction treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in Germany.
    Bischoff, H.
    Hermes, A.
    Gatzemeier, U.
    Heigener, D. F.
    Cesaro-Tadic, S.
    Walzer, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study
    Santoro, Armando
    Hillerdal, Gunnar N.
    Hoeffkenc, Gert
    Favaretto, Adolfo
    Carrion, Ramon Perez
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Helsberg, Karin
    Soldatenkova, Victoria
    Bourayou, Nawel
    Sorensen, Jens B.
    LUNG CANCER, 2014, 86 (01) : 47 - 53
  • [23] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [25] Efficacy and Safety of 8 spheres Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Locally Advanced Non-small Cell Lung Cancer
    Wang, Xiaojun
    Zhang, Huiyun
    Zhou, Liangfen
    Ou, Hui
    Liu, Hengyu
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2023, 38 (05) : 313 - 321
  • [26] Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Mengzhao
    Qin, Shukui
    Lu, You
    Zhang, Yang
    Zhu, Yunzhong
    Song, Xiangqun
    Wang, Xin
    Barraclough, Helen
    Zhang, Xiaoqing
    Chi, Haidong
    Orlando, Mauro
    LUNG CANCER, 2014, 85 (03) : 401 - 407
  • [27] Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer
    Noor, Zorawar S.
    Goldman, Jonathan W.
    Lawler, William E.
    Telivala, Bijoy
    Braiteh, Fadi
    DiCarlo, Brian A.
    Kennedy, Kathleen
    Adams, Brad
    Wang, Xiaoyan
    Jones, Benjamin
    Slamon, Dennis J.
    Garon, Edward B.
    LUNG CANCER, 2019, 135 : 104 - 109
  • [28] A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell lung cancer (NSCLC) in Germany
    Heigener, D. F.
    Wiesner, C.
    Aultman, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Ganju, Vinod
    Pereira, Jose
    Kim, Joo-Hang
    Magallanes, Manuel
    Lee, Dae-Ho
    Wang, Jie
    Martinez, Luis
    Barraclough, Helen
    Van Kooten, Maximiliano
    Orlando, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S417 - S418
  • [30] Comparison of pemetrexed plus cisplatin versus pemetrexed plus carboplatin in the initial treatment of locally advanced or metastatic non-small cell lung cancer
    Pereira, A. A. R.
    Lessa, R. C.
    Souza, C. E. P.
    Pinto, F. A. I.
    Gagliato, D. M.
    Santos, E. S.
    Fanelli, M. F.
    Rinck, J. A.
    Dettino, A. A.
    Nicolau, U. R.
    Chinen, L. T. D.
    de Lima, V. C. C.
    Pereira, J. R.
    Cruz, M. R. D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345